Patents Assigned to Texas Tech University System
  • Patent number: 11492669
    Abstract: The present invention includes a method for identifying an Alzheimer's disease (AD) patient prior to reaching clinical disease classification, comprising: obtaining a dataset associated with a blood, serum, or plasma sample from the patient, wherein the dataset comprises data representing the level of one or more microRNA biomarkers in the blood, serum, or plasma sample; assessing the dataset for a presence or an increase in an amount of miRNA-455-3p; determining the likelihood that the patient will develop AD patient prior to reaching clinical disease classification by detecting the presence or the increase in miRNA-455-3p to produce a score that is indicative of a likelihood of developing AD, wherein a higher score relative to a healthy control indicates that the patient is likely to have the prognosis for transitioning to classified AD, wherein the healthy control is derived from a non-AD patient with no clinical evidence of AD.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 8, 2022
    Assignee: Texas Tech University System
    Inventors: P. Hemachandra Reddy, Subodh Kumar
  • Patent number: 11471411
    Abstract: The present invention includes compositions, methods, and methods of making and using a nanoscale discoidal membrane comprising: an amphiphilic membrane patch comprising self-assembled molecular amphiphiles capable of supporting one or more membrane proteins in the amphiphilic membrane patch; and one or more amphipathic scaffold macromolecules that encase the nanoscale discoidal membrane.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: October 18, 2022
    Assignee: Texas Tech University System
    Inventors: Guillermo A. Altenberg, Hongjun Liang
  • Publication number: 20220288159
    Abstract: Embodiments of the present disclosure pertain to methods of treating or preventing Alzheimer's disease or symptoms of Alzheimer's disease in a subject by administering to the subject an active agent that includes an adenovirus-36 E4orf1 protein, a nucleic acid encoding an adenovirus-36 E4orfl protein, or combinations thereof. Additional embodiments of the present disclosure pertain to the active agents of the present disclosure for use in the treatment or prevention of Alzheimer's disease or symptoms of Alzheimer's disease.
    Type: Application
    Filed: August 7, 2020
    Publication date: September 15, 2022
    Applicant: Texas Tech University System
    Inventors: Nikhil V. Dhurandhar, Vijay Hegde
  • Publication number: 20220233554
    Abstract: Embodiments of the present disclosure pertain to methods of treating a cancer in a subject by administering to the subject a compound that inhibits interaction between octamer-binding transcription factor 4 (OCT4) and Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), OCT4 and DNA-dependent protein kinase catalytic subunit (DNA-PKcs), or combinations thereof. Additional embodiments of the present disclosure pertain to the compounds of the present disclosure. Further embodiments of the present disclosure pertain to methods of inhibiting interaction between OCT4 and MAPKAPK2 and/or OCT4 and DNA-PKcs by exposing protein complexes to the compounds of the present disclosure. Additional embodiments of the present disclosure pertain to methods of screening potential inhibitors of protein-protein interaction between a first protein and a second protein.
    Type: Application
    Filed: February 8, 2022
    Publication date: July 28, 2022
    Applicant: Texas Tech University System
    Inventors: Min H. Kang, Sung-Jen Wei, Charles P. Reynolds
  • Patent number: 11395804
    Abstract: The present invention includes compositions and methods of making hydrophilic nanostructured antibiotics (i.e. nanoantibiotics), including nanoantibiotics that use environmentally degradable biomolecules as the backbone building blocks, wherein the backbone building blocks can include spherical backbones such as sucroses, cyclodextrins, glycogens, and phytoglycogen with different diameters, or rod-like backbone building blocks such as dextrins, amyloses, and celluloses with different lengths. These hydrophilic nanoantibiotics with well-defined sizes and shapes can selectively disrupt bacterial membranes (i.e., serve as membrane-active antimicrobials) while being benign to mammalian cells. Depending on the size and shape difference of the hydrophilic nanoantibiotics, they can also selectively kill one type of bacteria (e.g., gram-negative) over another type (e.g., gram-positive).
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: July 26, 2022
    Assignee: Texas Tech University System
    Inventor: Hongjun Liang
  • Patent number: 11389526
    Abstract: The present invention includes a live, self-attenuated therapeutic vaccine, virus and methods of making and using the same, comprising: an isolated virus comprising a viral genome that expresses one or more viral antigens; and an artificial microRNA 30 (amiR-30) expression cassette inserted into a viral neuraminidase (NA) or a viral non-structural (NS) gene segment that expresses an amiR-30 that specifically inhibits the expression of a host gene essential for influenza virus replication in host cells.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: July 19, 2022
    Assignee: Texas Tech University System
    Inventors: Mingtao Zeng, Ke Wen
  • Patent number: 11369593
    Abstract: The present invention includes compositions and methods for treating a subject afflicted with a neurodegenerative disorder or disease by determining that the subject is in need of treatment for the neurodegenerative disorder or disease; and administering to the subject an amount of an effective amount of a compound comprising a flupirtine derivative as disclosed herein.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 28, 2022
    Assignee: Texas Tech University System
    Inventors: Paul Trippier, Nihar Kinarivala, Rose-Mary Boustany
  • Patent number: 11357247
    Abstract: An eggless mayo is provided that is heat stable or that is heat stable as well as freeze-thaw stable and that is all natural. In addition a mayonnaise composition is provided that has increased heat stability as well as freeze-thaw stability. A low-salt version of the eggless mayo is provided as well as compositions for various butters and creams that have enhanced heat stability as well as freeze-thaw stability.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: June 14, 2022
    Assignee: Texas Tech University System
    Inventor: Richard S. Meyer
  • Patent number: 11357766
    Abstract: The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin or derivatives thereof in an amount sufficient to treat the reproductive cancer in the subject and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 14, 2022
    Assignee: Texas Tech University System
    Inventors: Sanjay K. Srivastava, Sharavan Ramachandran
  • Patent number: 11332555
    Abstract: The present invention includes compositions, methods, and methods of making and using a polymer-encased nanodisc comprising: one or more integral membrane proteins in a lipid layer; and a polymer comprising zwitterionic styrene-maleic acid derivative repeating units that carry zero or nearly zero negative charge, and the polymer-encased nanodiscs.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: May 17, 2022
    Assignee: Texas Tech University System
    Inventors: Guillermo A. Altenberg, Hongjun Liang
  • Patent number: 11318199
    Abstract: Methods and devices are provided for treating a food allergy in a subject in need thereof. The method entails delivering an effective amount of an allergen associated with the food allergy into the subject's cutis skin layer. Delivering the allergen is carried out by inserting one or more allergen-coated solid microneedles into the subject's skin. The one or more solid microneedles each has a base, shaft and tip, and when inserted in the subject, do not extend beyond the cutis. The allergen is allowed to dissociate from the one or more microneedles while inserted in the subject's cutis. Once the allergen disassociates, the one or more microneedles is removed from the subject's skin.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: May 3, 2022
    Assignee: Texas Tech University System
    Inventors: Harvinder Singh Gill, Akhilesh Kumar Shakya
  • Patent number: 11311617
    Abstract: Methods and devices are provided for treating a food allergy in a subject in need thereof. The method entails delivering an effective amount of an allergen associated with the food allergy into the subject's cutis skin layer. Delivering the allergen is carried out by inserting one or more allergen-coated solid microneedles into the subject's skin. The one or more solid microneedles each has a base, shaft and tip, and when inserted in the subject, do not extend beyond the cutis. The allergen is allowed to dissociate from the one or more microneedles while inserted in the subject's cutis. Once the allergen disassociates, the one or more microneedles is removed from the subject's skin.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: April 26, 2022
    Assignee: Texas Tech University System
    Inventors: Harvinder Singh Gill, Akhilesh Kumar Shakya
  • Patent number: 11286502
    Abstract: The present invention includes compositions, methods, vectors, vaccines, cell lines and other constructs for making and used Zika virus Reporter Virus Particles (RVPs) and/or Virus Like Particles (VLPs) that are safe for handling and manufacturing and are able to generate an effective immune response against Zika virus and can be readily scaled up for cost-effective production.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 29, 2022
    Assignee: Texas Tech University System
    Inventors: Himanshu Garg, Anjali Joshi
  • Publication number: 20220071953
    Abstract: In an embodiment, the present disclosure pertains to compositions and methods for modulating cellular glucose uptake. In general, the methods include associating cells with the compositions of the present disclosure. In another aspect, the present disclosure pertains to compositions and methods to treat or prevent a disorder in a subject. The methods generally include administering the compositions of the present disclosure to the subject.
    Type: Application
    Filed: January 8, 2020
    Publication date: March 10, 2022
    Applicant: Texas Tech University System
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • Patent number: 11266624
    Abstract: The present invention includes a method and compositions for preventing primary or acquired resistance of epidermal growth factor receptors (EGFR) inhibitors in a cancer with deregulated EGFR comprising: identifying a subject suspected of needing treatment for primary or acquired resistance to epidermal growth factor receptor (EGFR) inhibitors of the cancer with deregulated EGFR; and providing the subject with a therapeutically effective amount of a chromosome region maintenance 1 (CRM1) inhibitor and an inhibitor of EGFR in an amount sufficient to reduce or eliminate the cancer.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: March 8, 2022
    Assignee: Texas Tech University System
    Inventor: Weimin Gao
  • Publication number: 20220065765
    Abstract: Disclosed is a system for determining fecundity of an embryo utilizing a non¬invasive grading of early stage embryos (pre-hatching) based upon specific gravity, density and/or estimated weight. The system allows 100% recovery of embryos and can detect differences in growth potential at the earliest stages of development. The system may further enhance the development of embryos by utilization of microfluidic effects during use. The disclosed system supports a wide variety of scenarios for human and animal reproductive technologies and related products and services.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 3, 2022
    Applicant: Texas Tech University System
    Inventors: Samuel D. Prien, Lindsay L. Penrose
  • Publication number: 20220054105
    Abstract: The present disclosure provides using ultrasound technology and artificial intelligence to enhance MSR assessment by making the assessment more objective, reproducible, and recordable to allow a more precise and/or personalized approach to the medical practice of individual patients via using multiple ultrasound functions and artificial intelligence to improve the accuracy and consistency of assessing reflexes and allowing MSR data to be combined with other patient medical information for improved diagnosis and management of a patient's condition.
    Type: Application
    Filed: August 24, 2021
    Publication date: February 24, 2022
    Applicants: University of South Carolina, Texas Tech University System
    Inventors: Richard Hoppmann, Jongyeol Kim
  • Publication number: 20220018797
    Abstract: The present invention provides for a device and method for the rapid detection (within seconds) of viruses and virions (proteins and nucleic acids) found in novel coronavirus (SARS-CoV-2) and other viruses through testing of an air sample. The device can be used at front line, hospitals, clinical laboratories, airports, groceries, homes, and the like. The device can be used as a single probe for single use or home use for fast detection of multiple samples simultaneously. The present invention would facilitate multiple testing at times of pandemics caused by airborne viruses when a large number of samples have to be tested in short periods of time.
    Type: Application
    Filed: July 12, 2021
    Publication date: January 20, 2022
    Applicant: Texas Tech University System
    Inventors: Gerardine G. Botte, Ashwin Ramanujam
  • Patent number: 11225459
    Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea compounds acts by blocking at targeted receptors in the brain that contribute to the increase in inflammation. Combinations of receptors, H1 receptor, H2 receptor, dopamine transporter (DAT), and/or 5HT3C receptor, are individually and/or collectively inhibited by the same compositions of the present disclosure, and this ability leads to a decrease in brain edema. The DAT inhibitory effects additionally maintains dopamine levels in a patient.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: January 18, 2022
    Assignee: Texas Tech University System
    Inventors: Nadezhda German, Mikelis Constantinos
  • Publication number: 20210401410
    Abstract: The present invention relates in general to the improved containment of biological fluids. In particular, a method and apparatus for collection and preservation of fluid samples in accordance with the present invention results in collection of semen having improved viability both at the time of collection and after storage. The disclosed methods and apparatuses methods support a wide variety of applications for containment of biological fluids related to human and veterinary medicine including, but not limited to, human reproductive medicine and animal husbandry.
    Type: Application
    Filed: June 30, 2021
    Publication date: December 30, 2021
    Applicants: Texas Tech University System, RSI Technology Group, LLC
    Inventors: Samuel D. Prien, Lindsay L. Penrose, Diana M. Peninger